Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 1 · 50%High 1 · 50%

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Grade 3 to 4 neutropenia · adjuvant therapy for early breast cancer

Taxane followed by anthracyclines leads to lower adverse events: neutropenia (grade 3/4) ( compared with anthracyclines followed by taxane (high certainty).

1 finding from 1 review

Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
RR 0.62 [0.4, 0.97]
4 studies · 279 participants
High

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Grade 3 to 4 neutropenia · neoadjuvant therapy for early breast cancer

Taxane followed by anthracyclines showed no clear difference in adverse events: neutropenia (grade 3/4) ( compared with anthracyclines followed by taxane (moderate certainty).

1 finding from 1 review

Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
RR 1.25 [0.86, 1.82]
1 study · 280 participants
Moderate